logo
Select company
Select metric
$ -49.23MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
13
Sector
33
Industry
47
History
27
$ 2.02Close
$ 1.52 - $ 4.62 52-Week Range
Ticker Information

Ticker

MREO

Company Name

MEREO BIOPHARMA GROUP PLC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

MEREO BIOPHARMA GROUP PLC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

MREO - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 1.12M$ -50.35M$ -49.23M
3/31/2025$ 1.08M$ -47.31M$ -46.22M
12/31/2024$ 1.09M$ -43.53M$ -42.44M
6/30/2024$ 1.09M$ -36.76M$ -35.67M
12/31/2023$ 1.06M$ -28.4M$ -27.34M
6/30/2023$ 868.75K$ -31.42M$ -30.55M
12/31/2022$ 908.75K$ -40.91M$ -40.01M
6/30/2022$ 1.02M$ -15.83M$ -14.8M
12/31/2021$ 802.5K$ 22.83M$ 23.63M
6/30/2021$ 1.05M$ -148.38M$ -147.33M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • MEREO BIOPHARMA GROUP PLC's latest trailing twelve months (TTM) EBITDA stands at $ -198.09M.
  • Over the past 5 years, MEREO BIOPHARMA GROUP PLC's average EBITDA has been $ -55.28M.
  • The median EBITDA for MEREO BIOPHARMA GROUP PLC during this period was $ -40.01M
  • MEREO BIOPHARMA GROUP PLC reached its highest EBITDA over the past 5 years at $ 23.63M.
  • The lowest EBITDA recorded by MEREO BIOPHARMA GROUP PLC in the same timeframe $ -198.09M

MEREO BIOPHARMA GROUP PLC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
CRDF : CARDIFF ONCOLOGY INC $ -50.37MABEO : ABEONA THERAPEUTICS INC $ 79.97MHUMA : HUMACYTE INC $ -40.8MAVTX : AVALO THERAPEUTICS INC $ -47.9MCOYA : COYA THERAPEUTICS INC $ -21.03MABVC : ABVC BIOPHARMA INC $ -2.42MFDMT : 4D MOLECULAR THERAPEUTICS INC $ -189.01MVTGN : VISTAGEN THERAPEUTICS INC $ -55.12MERNA : ERNEXA THERAPEUTICS INC $ -37.86MANNX : ANNEXON INC $ -183.37M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for MEREO BIOPHARMA GROUP PLC is calculated as follows: EBIT [ $ -200.08M ] + DepAmor [ $ 2M ]
(=) EBITDA [ $ -198.09M ]

MREO - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -198.09M

Minimum

Dec 31, 2020

$ 23.63M

Maximum

Dec 31, 2021

$ -55.28M

Average

$ -40.01M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.77M with a standard deviation of $ 166.95M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.77M
median$ 8.83M
std$ 166.95M